Pharma News
05 Apr 2026 to 11 Apr 2026
Apr 11, 2026
Glioblastoma: Patent Application Under Review - WEEK
A research team led by Dr. Kiran Velpula at the University of Illinois College of Medicine in Peoria has made progress in developing a new treatment for Glioblastoma, a deadly brain cancer. A provisional patent has been granted for their promising compound, which targets specific biomarkers and aims to be less toxic than current options. The team is now pursuing a full patent.
Apr 11, 2026
Apotex's Generic Version of Ozempic Approved by FDA: A Challenge to Novo Nordisk's Dominance?
Apotex Corp. has received tentative FDA approval for its generic version of Ozempic (semaglutide injection), challenging Novo Nordisk's monopoly in the GLP-1 drug market. While this approval could lower prices and increase access for patients, Apotex must navigate patent issues and regulatory hurdles before launching. Novo Nordisk's patents are expected to last until 2031-2032.
Apr 11, 2026
Rothschild & Co Redburn Increases Eli Lilly's Price Target to $880 - Indianapolis Today
Eli Lilly and Company (NYSE: LLY) received a price target increase from $875 to $880 by Rothschild & Co Redburn, which maintained a neutral rating. The firm highlighted Eli Lilly's strong financial performance and promising drug development as key factors for the adjustment, noting the company's outperformance in the pharmaceutical sector.
Apr 11, 2026
Ozempic has become affordable enough to make a global impact - GNN
The expiration of the semaglutide patent in India has led to the launch of affordable generics of Ozempic, with prices starting at $14 a month, compared to $349 in the US. This could significantly impact India's high rates of obesity, diabetes, and cardiovascular disease, potentially marking a major public health breakthrough.
Apr 11, 2026
Be cautious of the rise in inexpensive generic Ozempic weight loss medications available in Asia.
The patent for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, expired on March 20, allowing Indian companies like Dr Reddy's Laboratories and Zydus Life Sciences to launch generic versions at up to 70% lower prices. This shift could significantly impact diabetes and obesity treatment in Asia, raising concerns over regulatory control and potential misuse of GLP-1 drugs.
Apr 11, 2026
Apotex Receives Tentative Approval for Generic Ozempic, Posing Challenges for Novo Nordisk | Whalesbook
Apotex Corp., in collaboration with Orbicular Pharmaceutical Technologies, has received tentative FDA approval for a generic semaglutide injection, similar to Novo Nordisk's Ozempic. This approval could enhance patient access and reduce costs in the GLP-1 drug market, although full market entry depends on resolving patent issues. The move signals increased competition in the multi-billion dollar diabetes and weight-loss treatment sector.
Apr 10, 2026
Novo Nordisk A/S shares (DK0060534915): How solid is its leading position in the obesity medication market? - Ad-hoc-news.de
Novo Nordisk A/S is positioned as a leader in the GLP-1 market with blockbuster drugs like Ozempic and Wegovy, addressing rising obesity and diabetes rates in the U.S. The company's focus on chronic disease innovation and strategic partnerships supports its growth amid increasing demand. Analysts maintain a positive outlook, emphasizing Novo's resilience and potential for sustained returns despite competitive pressures.
Apr 10, 2026
FDA Unveils Preliminary Guidelines for Confirming Non-Animal Testing Approaches (NAMs) in Pharmaceuticals ...
The FDA has released draft guidance on March 18, 2026, titled "General Considerations for the Use of New Approach Methodologies in Drug Development." This guidance aims to validate non-animal testing methods (NAMs) in drug development, as issued by the Center for Drug Evaluation and Research (CDER).
Apr 10, 2026
CDSCO Expedites Approvals for Importing Foreign Medications to Reduce Wait Times - Drug Regulation
The Central Drugs Standard Control Organisation (CDSCO) has expedited the approval process for foreign drug imports by fast-tracking Form 40 applications, aiming to reduce delays in bringing new medications to India. This initiative, announced on April 7, 2026, is expected to enhance the availability of foreign pharmaceuticals in the Indian market.
Apr 10, 2026
Canada's Inactive DIN Issue: The Impact of Marketing Status on Pharmaceutical Intellectual Property
Canada's treatment of "dormant" Drug Identification Numbers (DINs) is creating uncertainty in its pharmaceutical regulatory framework, impacting intellectual property (IP) protections under the Canada–United States–Mexico Agreement (CUSMA). The current policy ties patent protections to the marketing status of individual DINs, which may disincentivize innovation and misalign with CUSMA's commitments. Legislative amendments are suggested to address these issues.
Apr 10, 2026
Impact of Patent Expiration: Eli Lilly Faces Market Share Decline Amid Rise of Generic Weight-Loss Medications...
Eli Lilly's market share in India dropped from 61% to 56% in March following the expiration of the semaglutide patent, allowing cheaper generics to flood the market. In contrast, Novo Nordisk's share remained steady at 25%. Experts predict further declines for Eli Lilly's tirzepatide brands as 13 Indian companies launch 26 generic semaglutide products.
Apr 10, 2026
Eli Lilly Introduces GLP-1 Pill Foundayo Through LillyDirect and Telehealth Services Nationwide
Eli Lilly has launched Foundayo, a once-daily oral GLP-1 obesity treatment, available through its LillyDirect cash-pay channel and telehealth providers in the U.S. The drug may cost as low as $25 monthly. However, Eli Lilly faces declining sales due to the influx of generic GLP-1s in India, impacting its Mounjaro product.
Apr 10, 2026
Bristol Myers Squibb's stock (US1101221083): Does its cancer treatment pipeline have the potential to drive growth?
Bristol Myers Squibb faces challenges with upcoming patent expirations for key drugs like Eliquis and Opdivo, raising concerns about future growth. However, analysts remain optimistic about the company's oncology and immunology pipeline, suggesting potential for stock appreciation. With a strong focus on U.S. markets and a robust dividend, Bristol Myers Squibb is positioned as a resilient investment for U.S. investors.
Apr 10, 2026
What Makes the First Oral Non-Peptide GLP-1 Agonist More Significant Than It Appears? | MEXC News
Orforglipron, the first nonpeptide oral GLP-1 agonist, offers a revolutionary alternative to injectable diabetes and weight-loss medications like semaglutide and tirzepatide. Demonstrating significant efficacy in lowering HbA1c and promoting weight loss, orforglipron enhances patient adherence by eliminating injection-related discomfort. Its simpler manufacturing process promises cost-effectiveness, making it a viable solution for global metabolic health challenges.
Apr 10, 2026
Can Sanofi S.A. (FR0000127771) leverage its emphasis on rare diseases to generate potential growth?
Sanofi is enhancing its focus on high-margin rare disease drugs, appealing to U.S. investors seeking stability amid market volatility. The company’s flagship product, Dupixent, generates significant revenue, while its diversified portfolio and strong R&D investments position it well for future growth. Analysts view Sanofi positively, highlighting its potential in immunology and rare diseases as key growth drivers.
Apr 9, 2026
Novo Nordisk's patent expiration for its weight-loss medication ignites a surge of interest among generic pharmaceutical companies.
India's weight-loss drug market is transforming as generic versions of Novo Nordisk's semaglutide become available at lower prices, affecting Eli Lilly's sales. The rapid launch of affordable alternatives by Indian drugmakers signals significant growth in obesity treatments in the country.
Apr 9, 2026
Eli Lilly's Mounjaro Faces Competition from Affordable Semaglutide Generics in India | Whalesbook
Eli Lilly's obesity drug Mounjaro faces declining sales in India due to the emergence of cheaper generic versions of Novo Nordisk's semaglutide, following its patent expiry. Mounjaro's sales dropped nearly 16% in March, while semaglutide generics surged. Industry experts predict a 'gold rush phase' for domestic players, with aggressive pricing strategies shaping the market's future.
Apr 9, 2026
Genetic factors could clarify why Wegovy and Mounjaro are more effective for certain individuals - VegOut
A new study published in Nature reveals that genetic variants significantly influence weight loss outcomes for drugs like Wegovy and Mounjaro, with disparities more common among individuals of European ancestry. This research highlights the need for personalized medicine in prescribing these medications, as genetic profiling could optimize treatment effectiveness and address existing racial and economic disparities in drug access and outcomes.
Apr 9, 2026
Understanding the High Cost of Medications: The Role of Pharmaceutical Monopolies - KUOW
A new series, "An Arm and a Leg 101," explores why drug prices are high, highlighting the pharmaceutical industry's legal tactics to maintain monopolies and block generics. Al Engelberg, instrumental in shaping the generic drug industry, reflects on the mixed legacy of his work, which has led to both savings and increased costs for consumers, with over 20% of Americans skipping medications due to affordability.
Apr 9, 2026
Upcoming U.S. aid interruption: Medications for HIV and malaria in Africa and Asia - Healthbeat
The U.S. is proposing a major overhaul of its HIV and malaria aid delivery, risking medicine shortages across Africa and Asia. The Global Health Supply Chain Program, managed by Chemonix, may be replaced by new systems, raising concerns about service continuity. Meanwhile, the rollout of the HIV prevention drug lenacapavir faces supply challenges in Eswatini, despite high demand.
Apr 9, 2026
Generic versions of weight loss medications in India impact Eli Lilly's revenue - Moneycontrol.com
Following the expiration of semaglutide's patent on March 20, Indian drugmakers rapidly introduced generics, capturing a 33% market share in the GLP-1 segment by March. Torrent Pharmaceuticals leads with an 8% share, while Eli Lilly's Mounjaro sales fell to Rs 114 crore. The surge in generics is reshaping India's obesity market, prompting price cuts from Novo Nordisk.
Apr 9, 2026
Government to Launch Real-Time Digital Platform for Monitoring NDPS Drugs Following Increase in Codeine Syrup Usage
The Central Government of India plans to launch a real-time digital portal to track narcotic drugs and psychotropic substances (NDPS) amid rising concerns over the misuse of codeine syrup and other narcotics. This initiative aims to enhance monitoring and prevent diversion of pharmaceutical products regulated under the Narcotic Drugs and Psychotropic Substances Act.
Apr 9, 2026
Generic versions of Semaglutide impact Mounjaro's sales and market presence following patent expiration | Industry Update
Following the patent expiration of semaglutide on March 20, over 23 generics entered the market, boosting its sales by 23% to ₹59 crore in March. Meanwhile, Eli Lilly's Mounjaro (tirzepatide) saw a 15% decline in sales to ₹114 crore but remained the top-selling drug in FY26 with ₹923 crore. The generics' lower pricing is reshaping the GLP-1 market dynamics.
Apr 9, 2026
AstraZeneca and Sun Resolve Patent Disputes Concerning Three Diabetes Medications - Bloomberg Law News
AstraZeneca Plc and Sun Pharmaceutical Industries Ltd. have agreed to dismiss three lawsuits regarding patent infringement claims related to AstraZeneca's diabetes treatments Farxiga, Qtern, and Xigduo XR. The lawsuits, which involved US Patent No. 6,515,117 covering dapagliflozin, were resolved after the patent expired last week, with the possibility of future allegations remaining open.
Apr 9, 2026
Russia Launches the First Personalized mRNA Cancer Vaccine 'Neooncovac' for...
Russia has made a significant advancement in cancer treatment by administering the world's first personalized mRNA cancer vaccine, Neooncovac, to a melanoma patient. This groundbreaking development marks a historic milestone in oncology.
Apr 9, 2026
Pharmaceutical companies are increasing their acquisitions of biotech firms as they face upcoming patent expirations and have significant financial resources available.
Biopharmaceutical companies are actively acquiring smaller firms to prepare for patent expirations, with notable deals including Gilead Sciences' $7.8 billion purchase of Arcellx and Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals. Merck & Co. also acquired Terns Pharmaceuticals for $6.7 billion. This surge in M&A activity reflects a strategic response to impending patent cliffs and a focus on promising drug candidates.
Apr 9, 2026
Innovative CAR-T Treatment Significantly Reduces Size of Aggressive Brain Tumor in Just Five Days
An experimental CAR-T cell therapy has shown remarkable efficacy in treating recurrent glioblastoma, achieving near-complete tumor regression in just five days. This breakthrough offers new hope for patients battling this aggressive brain cancer, marking a significant advancement in cancer treatment.
Apr 9, 2026
Generics of Semaglutide Capture 33% Market Share as India's GLP-1 Sector Evolves - TradingView
A shift in the obesity drug market is underway in India, with Novo Nordisk's semaglutide gaining a 33% market share following its patent expiration, while Eli Lilly's Mounjaro (tirzepatide) saw a decline to 64%. Generic semaglutide is priced as low as $14, prompting pricing pressures and increased competition, potentially foreshadowing global trends as more patents expire.
Apr 9, 2026
Safeguarding patents to secure resources | The Star
The Malaysian Health Ministry is drafting patent linkage guidelines to ensure continued access to generic medicines during patent disputes. This initiative, part of Malaysia's commitments under the CPTPP, aims to balance access to affordable drugs while protecting innovator patents. The guidelines will apply to all pharmaceutical products, excluding biologics, and will not affect public health emergencies.
Apr 9, 2026
Insmed's Lung Drug Potential Remains Strong Despite Skin Trial Setback - MedCity News
Insmed's Brinsupri, an oral small molecule designed to inhibit DPP1, has failed in a Phase 2b trial for hidradenitis suppurativa, leading to the discontinuation of its development for this indication. Despite this setback, Brinsupri remains on track for blockbuster status in treating non-cystic fibrosis bronchiectasis, with projected peak sales of $7.4 billion by 2039.
Apr 9, 2026
Eli Lilly's Mounjaro experiences a decline in sales due to the influx of semaglutide generics in the Indian market | Industry Update
Novo Nordisk's semaglutide is reshaping India's obesity market, capturing 33% of the GLP-1 segment as generics flood in, impacting Eli Lilly's Mounjaro, which saw its share drop to 64%. Torrent Pharmaceuticals has emerged as a key player in the generics market. The shift signals a significant challenge for branded drugs as patents expire globally.
Apr 9, 2026
New research explores why weight loss medications are effective for some individuals but not for others - ThePrint
A recent study highlights the role of genetic variation in the effectiveness and side effects of GLP-1 receptor agonist drugs for weight loss. While genetics influence treatment outcomes, factors like diet and lifestyle also play a significant role. The research suggests potential for personalized medicine in predicting responses to GLP-1 therapies, though genetic testing is not yet ready for clinical use.
Apr 8, 2026
US FDA releases preliminary guidelines on exclusivity for new clinical investigations - Pharmabiz.com
In March 2026, the US FDA's CDER released draft guidance clarifying the criteria for 3-year New Clinical Investigation Exclusivity for drug products. This guidance aims to enhance understanding of exclusivity provisions, which incentivize pharmaceutical innovation. It outlines eligibility requirements for New Drug Applications and emphasizes the importance of new clinical investigations in securing exclusivity.
Apr 8, 2026
UK establishes zero tariff agreement with the US, resulting in higher drug costs | BioWorld
The UK has formalized a zero tariffs deal with the US, exempting UK pharmaceuticals from import tariffs. This agreement, initially made last December, coincides with the UK government's commitment to increase spending on patented drugs.
Apr 8, 2026
Insights on the Future of Biologics: Takeaways from the Hatch–Waxman Act - Hoover Institution
The FDA has approved 81 biosimilars since the Biologics Price Competition and Innovation Act (BPCIA) in 2009, with 21 achieving interchangeability. Despite initial reluctance from patients and physicians, recent findings show no safety differences between biosimilars and their originators. The FDA is modernizing interchangeability standards, potentially easing market entry for biosimilars, which could reduce drug costs by 10-13%.
Apr 8, 2026
Eli Lilly produces the top-selling medication globally. Will it maintain its success? - Sherwood News
Eli Lilly, the world's most valuable pharmaceutical company, faces concerns over its market position as competition in the GLP-1 sector intensifies. Analysts from HSBC issued a "sell" rating, citing potential market saturation. Despite this, Lilly's recent FDA approval of Foundayo, a new weight-loss pill, and significant investments in manufacturing and R&D signal its commitment to growth.
Apr 8, 2026
Genetic factors could shed light on why certain individuals experience limited weight loss with GLP-1 medications.
New research from 23andMe reveals that two gene variants may influence the effectiveness of GLP-1 weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). While the study suggests potential for personalized treatment, the impact of these variants on weight loss is modest, highlighting the complexity of individual responses to these medications.
Apr 8, 2026
Indian Pharmaceutical Leaders Compete for Drug Brands as Patent Expirations Accelerate | Whalesbook
India's pharmaceutical sector is experiencing a surge in legal disputes over drug brand names, with companies like Sun Pharma, Novo Nordisk, and Dr. Reddy's Laboratories engaged in high-stakes battles. These conflicts arise from patent expirations, leading to concerns over patient safety and market share. Regulatory gaps exacerbate the issue, prompting calls for stricter naming rules to prevent medication errors.
Apr 8, 2026
Alvotech shares: A pioneering biosimilar company with opportunities for worldwide expansion.
Alvotech, a Luxembourg-based biotech firm, is poised to capitalize on the growing biosimilars market, targeting high-cost drugs in immunology and ophthalmology. With products like AVT02 (an Eylea biosimilar) and AVT04 (a Humira biosimilar), Alvotech aims to reduce treatment costs by 20-40%. Strategic partnerships, including with Teva, enhance its market entry potential. Investors should monitor regulatory milestones and market developments.
Apr 8, 2026
NovaBridge Announces Encouraging Results for 2025 and Progress on Major Drug Candidates
NovaBridge Biosciences reported strong financial results for 2025, highlighting promising data for its investigational drugs, givastomig for gastric cancer and VIS-101 for wet AMD. Givastomig achieved a 75% response rate in Phase 1b studies and is eligible for an Accelerated Approval Pathway. VIS-101 showed robust results in Phase 2a trials. Both drugs are positioned for further studies in 2026.
Apr 8, 2026
Blau Farmacêutica S.A. shares: Growth in Latin America driven by biosimilars
Blau Farmacêutica S.A. is emerging as a leader in Brazil's pharmaceutical market, focusing on biosimilars and monoclonal antibodies. With a portfolio of over 100 products, including affordable versions of rituximab and trastuzumab, the company is well-positioned for growth. Its shares, trading as BLAU3, offer attractive valuations and dividend yields, appealing to global investors seeking exposure to Latin America's healthcare sector.
Apr 8, 2026
US Considers Imposing Tariffs as High as 100% on Certain Brand-Name Medications - Neurology Advisor
The U.S. plans to impose new tariffs on certain name-brand medicines, potentially reaching 100% on imported drugs under patent. Companies investing in U.S. manufacturing could see tariffs reduced to 20% or even zero with price matching. Critics warn this could raise costs and jeopardize investments. The tariffs aim to boost domestic drug production and lower prices.
Apr 8, 2026
Ozempic has become affordable enough to make a significant impact globally - Vox
The expiration of the semaglutide patent in India has led to over 40 manufacturers launching generic versions of the drug, sold for as low as $14 a month, compared to $349 in the US. This development could significantly improve public health by addressing obesity, diabetes, and cardiovascular risks in a country with a high prevalence of these conditions.
Apr 8, 2026
Owner of Massachusetts Spa Admits Guilt in Smuggling Fake Botox - Drug Enforcement
Rebecca Fadanelli, 38, former owner of Skin Beaute Med Spa in Massachusetts, pleaded guilty to smuggling counterfeit Botox and posing as a nurse. She pocketed $900,000 from illegal sales, highlighting the dangers of counterfeit drugs. The case underscores the risks associated with unregulated cosmetic procedures.
Apr 8, 2026
RenovoRx Obtains Initial Notice of Allowance for Japanese Patent Related to RenovoCath ...
RenovoRx has received its first Notice of Allowance for a Japanese patent related to its RenovoCath® device. This innovative technology enables targeted, local drug delivery through the vasa vasorum, enhancing treatment options in the pharmaceutical landscape.
Apr 8, 2026
The Rise of Generic Semaglutide in India | Perspective - Chemistry World
Generic drugmakers in India are preparing for the March 20, 2026 expiration of Novo Nordisk's semaglutide patents, anticipating a surge of lower-priced alternatives. The demand for semaglutide, alongside Eli Lilly’s tirzepatide, is rising due to increasing diabetes and obesity rates. India's drug regulator is enhancing oversight to prevent unauthorized versions as competition intensifies.
Apr 8, 2026
Pharmaceutical Firms Engage in Brand Name Showdown! Hear Before Patent Expiration ... - Whalesbook
In India's pharmaceutical sector, major companies like Sun Pharma, Dr. Reddy's Laboratories, and Novo Nordisk are engaged in legal battles over brand names due to patent expirations. The Bombay High Court ruled against Sun Pharma's competitor 'PANTOZED-40' and halted Dr. Reddy's 'Olymviq' for being too similar to Novo Nordisk's 'Ozempic', highlighting concerns over patient safety and market share.
Apr 8, 2026
Solvonis obtains its second US patent for PTSD medication development in just one week.
Solvonis Therapeutics PLC has received its second US patent in a week for its PTSD drug program, covering a series of monoamine modulators targeting serotonin, dopamine, and noradrenaline. The patent, US No. 12,595,269, is valid until February 2043. This follows the recent grant of US Patent No. 12,590,077 and supports the advancement of lead candidate SVN-114.
Apr 7, 2026
Bausch strikes agreement with rival regarding generic version of IBS medication | Americas
Argentina is shifting its intellectual property (IP) policies after years of strict patent regulations. The new reforms aim to revitalize the pharmaceutical sector, but the success of this transition will depend on how companies adapt to the changes.
Apr 7, 2026
Medicinal Tariffs Under 'National Security' Claims Decrease U.S. Safety - Reports
The White House's recent decision to impose import taxes on certain patented pharmaceuticals could jeopardize the U.S. prescription drug market, warns National Taxpayers Union President Pete Sepp. He argues that tariffs up to 100% may disrupt access and affordability, ultimately burdening taxpayers. Sepp advocates for fair trade negotiations instead of temporary tariffs to ensure innovation and competition in American healthcare.
Apr 7, 2026
Study reveals that Delhi, Punjab, and Telangana have the highest antibiotic consumption in India, according to DrugsControl Media Services.
A recent study revealed that antibiotic use in Delhi, Punjab, and Telangana is the highest in India, with Telangana ranking third. The overuse of antibiotics is contributing to increased antimicrobial resistance and the emergence of superbugs, which are resistant to even tertiary antibiotics. The findings were published in the Journal of Antimicrobial Resistance.
Apr 7, 2026
Resolution Reached in Patent Conflict Between Daiichi Sankyo and Seagen Regarding Cancer Treatment
Daiichi Sankyo announced the conclusion of its patent dispute with Seagen Inc. over antibody-drug conjugate technology, specifically involving Seagen’s U.S. Patent No. 10,808,039. The U.S. Court of Appeals for the Federal Circuit invalidated the patent, reversing a previous ruling that had favored Seagen and dismissed related appeals, effectively ending the litigation concerning Daiichi Sankyo's cancer treatment, Enhertu.
Apr 7, 2026
From Nothing to Full Force – New Section 232 Tariffs on Patented Medications and the High-Stakes Implications...
On April 2, 2026, President Donald Trump announced a new tariff regime targeting imported patented pharmaceuticals and their ingredients, imposing up to a 100% duty under Section 232 due to national security concerns. The plan includes incentives for onshoring and differentiated rates for allies, while generics and biosimilars are currently exempt but may face future scrutiny.
Apr 7, 2026
A Year of Care, Then Silence: India's approach to rare diseases and the challenges faced by patients...
Approximately 7,000 rare diseases affect 4-6% of the global population, with 75% of patients being children. In India, an estimated 3,112 infants are born with Spinal Muscular Atrophy (SMA) annually. A recent study in Uttar Pradesh revealed a carrier frequency of 1:38, highlighting the need for increased awareness and policy action regarding rare disease treatments.
Apr 7, 2026
Biogen partners with Alloy platform to enhance the development of ASO medications - Fierce Biotech
Alloy Therapeutics has announced a collaboration with Biogen to advance multi-target antisense oligonucleotide (ASO) therapeutics, leveraging Biogen's expertise in ASO technologies, including its spinal muscular atrophy drug Spinraza. The agreement includes upfront and milestone payments for Alloy, enhancing its genetic medicine capabilities. Alloy aims for greater potency, improved immunogenicity, and enhanced tissue targeting in this partnership.
Apr 7, 2026
AstraZeneca's advancement in liver cancer treatment positions Imfinzi to potentially become a highly successful medication.
AstraZeneca's Imfinzi has shown promising results in a phase three trial for treating unresectable hepatocellular carcinoma, significantly delaying disease progression compared to standard treatment. This breakthrough positions Imfinzi to potentially generate peak annual sales of $11 billion by 2030, solidifying its status as a super-blockbuster drug. The company anticipates further trial results for other cancers later this year.
Apr 7, 2026
Supreme People's Court Provides Guidance on Managing Paragraph I Declarations in Drug Patents...
On March 19, 2026, China's Supreme People's Court ruled on a case involving Amgen's drug apremilast and Shi Yao Pharmaceuticals' generic application. The court upheld the dismissal of Amgen's lawsuit due to the expiration of the patent during proceedings, clarifying principles on Paragraph I declarations and patent registration timing in China's drug patent linkage system.
Apr 7, 2026
Lundbeck and Biogaran compete in Milan and Paris for a medication aimed at treating alcohol dependence.
Lundbeck's nalmefene, marketed as Selincro in the EU for alcohol dependence, faces legal challenges from Biogaran and Tiefenbacher Group over two patents. The European Patent Office recently revoked another of Lundbeck's nalmefene patents. The ongoing legal disputes highlight the significant economic value of drugs combating alcohol addiction, as WHO estimates 400 million people suffer from alcohol use disorders globally.
Apr 7, 2026
Lexaria Commends Eli Lilly on the Approval of Foundayo(TM) - TradingView
Lexaria Bioscience Corp. announced the FDA approval of Eli Lilly's Foundayo™ (orforglipron) for obesity treatment, expanding oral GLP-1 options. CEO Richard Christopher emphasized the potential for Lexaria's DehydraTECH™ technology to reduce side effects. Foundayo™ offers advantages over Novo Nordisk's Wegovy™, but has reported higher adverse effects. Lexaria plans further testing of GLP-1 drugs to enhance patient experiences.
Apr 7, 2026
Red Light Holland Announces Ongoing Growth of Filament Health's PEX010 Clinical Trials
Red Light Holland Corp. announced three new license agreements and two research shipments for Filament Health Corp.'s psilocybin drug candidate, PEX010, in March 2026. Collaborations include studies at the University of Melbourne, Imperial College London, and the University of Calgary. The company is also in the process of acquiring Filament, which holds 76 patents and has received regulatory approvals for clinical trials.
Apr 7, 2026
Central procurement organizations will perform thorough evaluations of the claims made by domestic producers regarding 67 medications.
The Department of Pharmaceuticals (DoP) announced that central procurement agencies will perform due diligence on claims made by local manufacturers for 67 drugs. This decision comes as these agencies urgently require certain medications, and verification by the DoP is still pending.
Apr 7, 2026
Recent I-MAK report reveals tactics used by pharmaceutical companies to prolong monopoly pricing.
A new report by the Initiative for Medicines, Access & Knowledge (I-MAK) reveals that drug manufacturers use strategic patenting schemes to delay competition and maintain high prices for drugs like Pomalyst, Darzalex, and Trelegy Ellipta. These tactics, including patent thickets and formulation switches, extend monopolies well beyond original patent terms, costing Medicare nearly $10 billion annually.
Apr 7, 2026
Department of Pharmaceuticals developing a plan to enhance testing facilities for medical devices.
The Department of Pharmaceuticals (DoP) is developing a roadmap to enhance testing infrastructure for medical devices, facilitating a smoother transition to the new licensing regime. A task force has been established to address this initiative.
Apr 7, 2026
Patna Drug Operation Uncovered: ₹55 Lakh Worth of Government Medications Confiscated
Bihar Police and the State Drug Control Administration have uncovered a drug racket in Patna, seizing government medicines valued at ₹55 lakh. The operation revealed a mafia gang's scheme to divert these medicines by altering their original packaging.
Apr 7, 2026
Celltrion's Truxima biosimilar becomes the leading blood cancer therapy in the United States - KED Global
South Korea's Celltrion Inc. is expanding its focus beyond biosimilars, aiming to develop its own mRNA drugs. This move follows the success of its COVID-19 treatment, Regkirona, as the company seeks to innovate in the evolving pharmaceutical landscape.
Apr 6, 2026
Generic Pharmaceuticals Market: Overview, Trends, Growth Factors, and Future Projections (2026 to 2035)
The global generic drugs market is projected to grow from USD 359.71 billion in 2025 to approximately USD 903.45 billion by 2035, driven by rising healthcare costs, patent expirations, and increasing demand for affordable medicines. Key players include Mylan N.V., Teva Pharmaceutical Industries, and Pfizer Inc. The market is expanding due to technological advancements and government initiatives promoting generic drug use.
Apr 6, 2026
AI Model Forecasts Serious Adverse Reactions in Cancer Patients Based on FDA Information
A study in the Journal of Clinical Oncology Clinical Cancer Informatics reveals that machine learning (ML) can enhance early detection of serious adverse events (SAEs) in cancer patients by analyzing data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS). This advancement could significantly improve patient safety in oncology.
Apr 6, 2026
Novo Nordisk Implements Subscription Model to Address Market Challenges - Ad-hoc-news.de
Novo Nordisk is launching a subscription model for its weight-loss drug Wegovy to combat revenue decline and competition from Eli Lilly, which holds over 60% of the U.S. obesity medication market. The subscription plan aims to secure patient loyalty while the company awaits FDA approval for its new drug CagriSema, expected in 2026/2027.
Apr 6, 2026
Neurocrine Acquires Soleno for $2.9 Billion, Potentially Securing Its Next Major Pharmaceutical Success
Neurocrine Biosciences has announced a $2.9 billion acquisition of Soleno Therapeutics, which developed Vykat XR, the first FDA-approved drug for Prader-Willi syndrome. Vykat, an extended-release formulation of diazoxide choline, has shown strong market uptake and is projected to reach blockbuster status. The acquisition aims to enhance Neurocrine's portfolio, which includes the blockbuster drug Ingrezza.
Apr 6, 2026
Enveric Biosciences secures important US patent for its mental health medication.
Enveric Biosciences has secured a US patent for its mental health drug candidate EB-003, aimed at treating neurological disorders. The patent covers chemical compounds and methods for non-hallucinogenic neuroplastogens. CEO Joseph Tucker emphasized the importance of this patent in advancing EB-003 towards FDA submission and a Phase 1 clinical trial, enhancing the company's intellectual property portfolio.
Apr 6, 2026
Zacks Industry Analysis Spotlights Indivior Pharmaceuticals and Catalyst ... - TradingView
Zacks Equity Research highlights five small drug stocks poised for growth amid a sector recovery: Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics. The industry is benefiting from strong quarterly results, M&A activity, and innovation in areas like obesity and gene therapy, despite challenges such as pipeline setbacks and regulatory uncertainties.
Apr 6, 2026
Bausch and MSN Reach Agreement to Settle Trulance Patent Dispute - Bloomberg Law News
Apr 6, 2026
What Impact Will Skyrizi and Rinvoq Have on AbbVie's Immunology Sales in Q1? - TradingView
AbbVie (ABBV) is set to report its Q1 2026 results on April 29, focusing on its immunology segment following the loss of exclusivity for Humira. The company anticipates strong sales from Skyrizi and Rinvoq, estimated at $4.43 billion and $2.07 billion, respectively. Meanwhile, Humira sales are expected to decline significantly to $723 million. Competitors include Johnson & Johnson (JNJ) and Eli Lilly (LLY).
Apr 6, 2026
FDA issues caution to Novo Nordisk regarding breaches in safety reporting - 2 Minute Medicine
The FDA has issued a warning letter to Novo Nordisk for failing to report serious adverse drug events on time, raising concerns about safety surveillance for GLP-1 receptor agonists like semaglutide. The agency has requested a corrective action plan from the company, emphasizing the importance of timely adverse event reporting for patient safety.
Apr 6, 2026
Comparing High Yield and Sustainable Growth: The Reasons AbbVie's Dividend Outshines Pfizer's Even with a Smaller Distribution
AbbVie reported strong Q4 earnings with $17.82B in free cash flow, driven by its immunology drugs Skyrizi and Rinvoq, while Pfizer's revenue fell to $17.56B, facing sustainability issues with a 0.93x free cash flow coverage for its dividend. AbbVie’s dividend is well-supported, contrasting with Pfizer's reliance on borrowing to maintain its higher yield.
Apr 6, 2026
Court Mostly Approves Class Certification, While Limiting Walker Process Allegations Related to Biologics...
A Virginia court granted CareFirst class certification for Sherman Act claims against Johnson & Johnson (J&J) regarding alleged delays in biosimilar competition for the ulcerative colitis drug Stelara. The court denied J&J's summary judgment motions, citing unresolved factual disputes on market power and allowing some Walker Process claims to proceed, while narrowing others related to J&J's acquisition of Momenta patents.
Apr 6, 2026
Novo Declares That Weight-Loss Surge Is Only Getting Started - TradingView
Novo Nordisk's CEO Mike Doustdar emphasizes that the weight-loss drug market, particularly for drugs like Wegovy and Ozempic, is far from saturated. With millions of obese individuals in the U.S. not receiving treatment, the company plans to significantly reduce prices—Wegovy by 50% and Ozempic by 33%—to attract more patients amid rising competition from Eli Lilly.
Apr 6, 2026
Novo Nordisk A/S shares: The weight-loss trend continues — essential insights for investors
Novo Nordisk's CEO highlights significant untapped demand for weight-loss drugs like Ozempic and Wegovy, indicating a burgeoning market. The company, a leader in GLP-1 therapies, is investing heavily to scale production amid rising global obesity rates. Analysts maintain positive outlooks, emphasizing the stock's growth potential despite competition from Eli Lilly's Mounjaro and Zepbound.
Apr 5, 2026
Despite having access to popular obesity medications, certain individuals still struggle to shed pounds - Texas Metro News
Danielle Griffin, a New Mexico IT worker, struggled to lose weight on Wegovy, despite having access and insurance coverage. Experts warn that 20% of patients may not respond to obesity medications like Wegovy and Mounjaro. Griffin has since switched to Zepbound, which has helped her lose 7 pounds. Doctors emphasize the need for personalized treatment in obesity management.
Apr 5, 2026
India's pharmaceutical exports exceed $28 billion in the first 11 months of FY26, marking a 5.6% increase, according to Drug Control.
India's pharmaceutical exports reached $28.29 billion in the first 11 months of FY26, marking a 5.6% increase despite global challenges. This growth underscores the resilience of India's pharma sector in the international market.
Apr 5, 2026
Korea's Biotechnology Exports Exceed 6 Trillion Won in the First Quarter Despite Conflict Concerns - Seoul Economic Daily
South Korea's bio-health exports reached $4.16 billion in Q1 2023, driven by strong biosimilar demand, particularly in the U.S. and EU. The country leads in FDA biosimilar approvals and anticipates a 9% increase in sector exports this year. Samsung Biologics expanded its production capacity to 845,000 liters after acquiring a facility from GlaxoSmithKline.
Apr 5, 2026
Novo Nordisk Focuses on Local Partnerships and Price Reductions Amidst Increasing Competition from Generic Weight-Loss Medications
Novo Nordisk AG remains competitive in India's emerging weight loss treatment market despite the patent expiry of semaglutide, the active ingredient in its drugs Ozempic and Wegovy. The company has cut prices by 36% and 48% respectively to counter generic competition from firms like Sun Pharmaceutical and Zydus Lifesciences. Novo aims to leverage brand trust and local partnerships to maintain market presence.
Apr 5, 2026
Jim Cramer Predicts Eli Lilly's Weight Loss Medication Will Be Highly Successful - Insider Monkey
At the 8th Future Investment Initiative conference, Elon Musk predicted that humanoid robots could be worth $250 trillion by 2040, reshaping the global economy. Major investors like Bill Gates and Larry Ellison are backing AI advancements, with a focus on a lesser-known company poised to lead this revolution. A detailed report on this investment opportunity is available for $9.99 a month.
Apr 5, 2026
Bayer's Strategic Shift: Focus on U.S. Market in Pharmaceutical Overhaul
Bayer is realigning its pharmaceutical strategy towards the U.S. market, focusing on new blockbuster drugs like Nubeqa and Asundexian for growth, despite facing significant legal liabilities and a decline in Xarelto sales. The company's share price has rebounded 86% year-to-date, reflecting improved investor sentiment amid ongoing litigation challenges.
Apr 5, 2026
Novo Nordisk Reduces Prices of Ozempic and Wegovy in India to Compete with Generic Brands | Whalesbook
Novo Nordisk AG is reducing prices for its weight-loss drugs, Ozempic and Wegovy, in India by 36% and 48%, respectively, to compete with local generics from companies like Sun Pharma and Dr. Reddy's. Executive Vice-President Emil Larsen emphasized the importance of brand trust and partnerships to maintain market presence amid growing competition in the price-sensitive Indian market.
Apr 5, 2026
Delhi Police Dismantles Interstate Fake Drug Operation; ₹2 Crore in Counterfeit Medications Recovered
Delhi Police have dismantled an interstate racket producing counterfeit Schedule-H medicines, seizing spurious drugs worth ₹2 crore. The operation highlights ongoing efforts to combat the distribution of fake pharmaceuticals in the region.
